WallStreetZenWallStreetZen

NASDAQ: SNY
Sanofi Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Sanofi earnings were $10.7B for the trailing 12 months ending Jun 30, 2025, with 139.6% growth year over year. The latest SNY earnings report on Jun 30, 2025 announced Q2 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SNY reported annual earnings of $5.8B, with -3.5% growth. The next SNY earnings date is Oct 24, 2025.

SNY past earnings growth

How has SNY's earnings growth performed historically?

Company
139.57%
Industry
49.76%
Market
30.17%
SNY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
SNY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
SNY's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

SNY earnings history

Current Revenue
$50.7B
Current Earnings
$10.7B
Current Profit Margin
21.2%
SNY's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

SNY Return on Equity

Current Company
12.8%
Current Industry
60%
Current Market
26.6%
SNY's Return on Equity (12.8%)... subscribe to Premium to read more.
High Return on Equity Performance

SNY undefined

Current Company
7.2%
Current Industry
10.6%
SNY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when SNY announces earnings.

SNY undefined

Current Company
11.91%
Current Industry
18.3%
SNY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SNY vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
SNY$18.05B$10.74B-2.50%$4.34
GILD$10.97B$6.31B+5.22%$5.05
PFE$17.31B$10.75B-5.52%$1.89
AMGN$15.89B$6.62B-0.02%$12.32
BMY$13.07B$5.05B-56.56%$2.49
View Top General Drug Manufacturer Stocks

SNY earnings dates

Next earnings date
Oct 24, 2025

Sanofi Earnings Reports & History FAQ

What were Sanofi's earnings last quarter?

On SNY's earnings call on Invalid Date, Sanofi (NASDAQ: SNY) reported Q2 2025 earnings per share (EPS) of N/A, up N/A year over year. Total SNY earnings for the quarter were N/A. In the same quarter last year, Sanofi's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Sanofi stock.

When does Sanofi report earnings?

The next SNY earnings date is Invalid Date. Add SNY to your watchlist to be reminded of Sanofi's next earnings date.

Is Sanofi profitable or losing money?

As of the last Sanofi earnings report, Sanofi is currently profitable. Sanofi's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $10.74 billion, a 136.83% increase year over year.

What was SNY's earnings growth in the past year?

As of Sanofi's earnings date in Invalid Date, Sanofi's earnings has grown 139.57% year over year. This is 89.81 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 49.76%. SNY earnings in the past year totalled $10.74 billion.

What are Sanofi's earnings expectations?

The current EPS estimate for Sanofi's earnings report in Invalid Date is $1.73.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.